J Korean Ophthalmol Soc.  2011 Dec;52(12):1485-1489. 10.3341/jkos.2011.52.12.1485.

A Review of Nasal Retinopathy of Prematurity Cases

• Lee DC
• Kim KS
• Kim YC

• KMID: 2215153
• DOI: http://doi.org/10.3341/jkos.2011.52.12.1485

Abstract

PURPOSE
The present study evaluated the developmental characteristics and causes of nasal retinopathy of prematurity (ROP).
METHODS
A total of 111 eyes from 56 ROP-affected infants who had been treated with laser photocoagulation by retina specialists at the nasal site were examined. The gestational age at birth and diagnosis, location of the lesion, time, and number of laser photocoagulation therapies for nasal and temporal ROP were analyzed.
RESULTS
Thirty-three cases (29.7%) were diagnosed with nasal ROP. The mean gestational age at birth was 28.43 weeks for nasal ROP, and 29.44 weeks for temporal ROP (p = 0.022). Additionally, the average gestational age of infants who received laser photocoagulation was 36.61 weeks for nasal ROP, and 39.71 weeks for temporal ROP (p = 0.001). The average number of ROP laser photocoagulation trials was 2936.03 for nasal ROP, and 1611.83 for temporal ROP (p = 0.0001). No case was observed with a wider avascular area in the nasal retina than in the temporal retina. Additionally, compared to the temporal ROP, the nasal ROP showed significant difference in progression rates, 33.3% in the nasal group and 8.97% in the temporal group (p = 0.001).
CONCLUSIONS
Nasal ROP was due to the ROP lesions developing earlier in the nasal than the temporal retina, although not due to any atypically wider nasal avascular area. In these cases, nasal ROP showed more disease progression compared to temporal ROP.

Keyword

Avascular area; Laser photocoagulation therapy; Lesion; Mean gestational age; Nasal retinopathy of prematurity

MeSH Terms

Disease Progression
Diterpenes
Eye
Gestational Age
Humans
Infant
Light Coagulation
Parturition
Retina
Retinopathy of Prematurity
Specialization
Diterpenes

Reference

References

1. Terry TL. Retrolental fibroplasia in the premature infant: V. further studies on fibroplastic overgrowth of the persistent tunica vasculo-sa lentis. Trans Am Ophthalmol Soc. 1944; 42:383–96.

2. Hardy RJ, Palmer EA, Dobson V, et al. Risk analysis of prethres-hold retinopathy of prematurity. Arch Ophthalmol. 2003; 121:1697–701.

3. Watts P, Adams GG, Thomas RM, Bunce C. Intraventricular hae-morrhage and stage 3 retinopathy of prematurity. Br J Ophthalmol. 2000; 84:596–9.

4. Gibson DL, Sheps SB, Uh SH, et al. Retinopathy of pre-maturity-induced blindness: birth weight-specific survival and new epidemic. Pediatrics. 1990; 86:405–12.

5. Nissenkorn I, Yassur Y, Mashkowski D, et al. Myopia in premature babies with and without retinopathy of prematurity. Br J Ophthalmol. 1983; 67:170–3.

6. Hungerford J, Stewart A, Hope P. Ocular sequelae of preterm birth and their relation to ultrasound evidence of cerebral damage. Br J Ophthalmol. 1986; 70:463–8.

7. Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Cryotherapy for retinopathy of prematurity cooperative group. Arch Ophthalmol. 1988; 106:471–9.

8. Multicenter trial of cryotherapy for retinopathy of prematurity. One-year outcome-structure and function. Cryotherapy for retinopathy of prematurity cooperative group. Arch Opthalmol. 1990; 108:1408–16.

9. McNamara JA, Tasman W, Brown GC, Federman JL. Laser photocoagulation for stage 3+ retinopathy of prematurity. Ophthalmology. 1991; 98:576–80.

10. Hunter DG, Repka MX. Diode laser photocoagulation for threshold retinopathy of prematurity. A randomized study. Ophthalmology. 1993; 100:238–44.

11. Trese MT. Scleral buckling for retinopathy of prematurity. Ophthalmology. 1994; 101:23–6.

12. Zilis JD, de Juan E, Machemer R. Advanced retinopathy of prematurity. The anatomic and visual results of vitreous surgery. Ophthalmology. 1990; 97:821–6.

13. Keith CG, Kitchen WH. Ocular morbidity in infants of very low birth weight. Br J Ophthalmol. 1983; 67:302–5.

14. Tasman W. Management of retinopathy of prematurity. Ophthalmology. 1985; 92:995–9.

15. Ben-Sira I, Nissenkorn I, Kremer I. Retinopathy of prematurity. Surv Ophthalmol. 1988; 33:1–16.

16. Noonan CP, Clark DI. Trends in the management of stage 3 retinopathy of prematurity. Br J Ophthalmol. 1996; 80:278–81.

17. Early treatment for retinopathy of prematurity cooperative group. Revised indications for the treatment of retinopathy of pre-maturity: results of the early treatment for retinopathy of pre-maturity randomized trial. Arch Ophthalmol. 2003; 121:1684–94.

18. Cogan DG. Development and senescence of the human retinal vasculature. Trans Ophthalmol Soc UK. 1963; 83:465–89.

19. Patz A. The role of oxygen in retrolental fibroplasia. Pediatrics. 1957; 19:504–24.

20. Donahue ML, Phelps DL, Watkins RH, et al. Retinal vascular endothelial growth factor (VEGF) mRNA expression is altered in relation to neovascularization in oxygen induced retinopathy. Curr Eye Res. 1996; 15:175–84.

21. Kretzer FL, Mehta RS, Johnson AT, et al. Vitamin E protects against retinopathy of prematurity through action on spindle cells. Nature. 1984; 309:793–5.

22. Flynn JT. Retinopathy of prematurity. Pediatr Clin North Am. 1987; 34:1487–516.

23. Michaelson IC. The mode of development of the vascular system of the retina with some observations on its significance of certain retinal diseases. Trans Ophthalmol Soc UK. 1948; 68:157–80.

24. Nissenkorn I, Kremer I, Cohen S, Ben-Sira I. Nasal versus temporal preretinal vasoproliferation in retinopathy of prematurity. Br J Ophthalmol. 1989; 73:747–9.

25. Capone A Jr, Diaz-Rohena R, Sternberg P Jr, et al. Diode-laser photocoagulation for zone I threshold retinopathy of prematurity. Am J Ophthalmol. 1993; 116:444–50.

26. Palmer EA, Flynn JT, Hardy RJ, et al. Incidence and early course of retinopathy of prematurity. The cryotherapy for retinopathy of pre-maturity cooperative group. Ophthalmology. 1991; 98:1628–40.